Legal & General Group Plc boosted its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 1.2% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 234,667 shares of the specialty pharmaceutical company’s stock after purchasing an additional 2,829 shares during the period. Legal & General Group Plc owned approximately 0.39% of Jazz Pharmaceuticals worth $34,321,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Dimensional Fund Advisors LP grew its position in Jazz Pharmaceuticals by 49.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 229,898 shares of the specialty pharmaceutical company’s stock worth $35,750,000 after purchasing an additional 75,703 shares during the last quarter. JPMorgan Chase & Co. grew its position in Jazz Pharmaceuticals by 41.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,405,408 shares of the specialty pharmaceutical company’s stock worth $218,540,000 after purchasing an additional 410,031 shares during the last quarter. Summit Partners Public Asset Management LLC purchased a new position in Jazz Pharmaceuticals during the 2nd quarter worth $10,108,000. Fjarde AP Fonden Fourth Swedish National Pension Fund grew its position in Jazz Pharmaceuticals by 13.8% during the 2nd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 17,469 shares of the specialty pharmaceutical company’s stock worth $2,716,000 after purchasing an additional 2,121 shares during the last quarter. Finally, Janus Henderson Group PLC grew its position in Jazz Pharmaceuticals by 11,990.7% during the 2nd quarter. Janus Henderson Group PLC now owns 873,919 shares of the specialty pharmaceutical company’s stock worth $135,894,000 after purchasing an additional 866,691 shares during the last quarter. 91.30% of the stock is currently owned by institutional investors.

Several research analysts have issued reports on the stock. J P Morgan Chase & Co reissued a “buy” rating and set a $190.00 price objective on shares of Jazz Pharmaceuticals in a research report on Monday, September 18th. Royal Bank Of Canada reissued a “buy” rating and set a $210.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday, September 15th. BMO Capital Markets reaffirmed a “buy” rating and issued a $196.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, September 20th. Morgan Stanley initiated coverage on shares of Jazz Pharmaceuticals in a report on Thursday, October 5th. They issued an “equal weight” rating and a $155.00 target price on the stock. Finally, Goldman Sachs Group initiated coverage on shares of Jazz Pharmaceuticals in a report on Thursday, September 28th. They issued a “neutral” rating and a $165.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and nineteen have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $181.28.

In related news, SVP Iain Mcgill sold 8,000 shares of the business’s stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $133.42, for a total transaction of $1,067,360.00. Following the sale, the senior vice president now owns 28,383 shares of the company’s stock, valued at $3,786,859.86. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $153.52, for a total transaction of $153,520.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,352 shares of company stock worth $1,417,763. 4.30% of the stock is owned by insiders.

Shares of Jazz Pharmaceuticals PLC (NASDAQ JAZZ) opened at $138.97 on Friday. The company has a market cap of $8,083.13, a PE ratio of 16.92, a P/E/G ratio of 0.87 and a beta of 0.98. Jazz Pharmaceuticals PLC has a fifty-two week low of $101.37 and a fifty-two week high of $163.75. The company has a current ratio of 3.10, a quick ratio of 2.94 and a debt-to-equity ratio of 0.63.

COPYRIGHT VIOLATION WARNING: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/09/legal-general-group-plc-raises-holdings-in-jazz-pharmaceuticals-plc-jazz.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.